AGENDA

Venue: Delta Chelsea Hotel, Toronto
Date: Saturday, May 3rd, 2008
Time: 8:30 am – noon
Chairs: Dr. Greg Cairncross & Dr. Warren Mason

8:30 am WELCOME AND INTRODUCTION
Dr. W. Mason

ONGOING STUDIES

8:40 am CE.5 (EORTC 22033-26033): PRIMARY CHEMOTHERAPY WITH TEMOZOLOMIDE VS. RADIOTHERAPY IN PATIENTS WITH LOW-GRADE GLIOMAS AFTER STRATIFICATION FOR GENETIC 1P LOSS: A PHASE III STUDY
Drs. W. Mason & D. Rheaume

8:50 am CE.5S: THE SOCIOBEHAVIOURAL EFFECTS OF PRIMARY CHEMOTHERAPY WITH TEMOZOLOMIDE VS RADIOTHERAPY IN PATIENTS WITH LOW-GRADE GLIOMAS AFTER STRATIFICATION FOR GENETIC 1P LOSS: A PHASE III STUDY
Dr. M. Parkinson

9:00 am CE.6: A RANDOMIZED PHASE III STUDY OF TEMOZOLOMIDE AND SHORT-COURSE RADIATION VERSUS SHORT-COURSE RADIATION ALONE IN THE TREATMENT OF NEWLY DIAGNOSED Glioblastoma multiforme in elderly patients
Drs. N. Laperriere & J. Perry

9:15 am IND.162: A PHASE I STUDY OF TEMOZOLOMIDE AND RAD001C IN PATIENTS WITH MALIGNANT GLIOMA
Dr. W. Mason

PLANNED STUDIES

9:25 am CEC.1 (EORTC 26053-22054): PHASE III TRIAL COMPARING NO ADJUVANT CHEMOTHERAPY VERSUS ADJUVANT THERAPY UNTIL PROGRESSION FOR ANAPLASTIC GLIOMA WITHOUT 1P/19Q LOSS. AN EORTC/NCI-C/RTOG INTERGROUP STUDY
Drs. W. Mason & C. O’Callaghan

9:40 am CEC.2 (NCCTG N0577): PHASE III INTERGROUP STUDY OF RADIOTHERAPY VERSUS TEMOZOLOMIDE ALONE VERSUS RADIOTHERAPY WITH CONCOMITANT AND ADJUVANT TEMOZOLOMIDE FOR PATIENTS WITH NEWLY DIAGNOSED ANAPLASTIC OLIGODENDROGLIOMA OR ANAPLASTIC MIXED GLIOMA WITH CHROMOSOMAL CO-DELETIONS OF 1P AND 19Q
Dr. G. Cairncross
10:00 am  **REFRESHMENT BREAK**

**FUTURE STUDIES**

10:20 am  POST OPERATIVE RADIOSURGERY TO THE TUMOUR BED FOLLOWING RESECTION OF A SINGLE METASTASIS  
Dr. D. Roberge

10:40 am  TRIAL OF DCA IN GBM  
Drs. J. Easaw & P. Forsyth

11:00 am  **BRAIN DISEASE SITE STRATEGIC PLANNING**  
Dr. W. Mason

ACCRUAL TO NCIC CTG STUDIES

PHASE I/II PROGRAM - WORKSHOP

METASTATIC DISEASE TRIALS

12:00 pm  **ADJOURN**